Effectiveness and Continuation Rate of Half-dose Janus Kinase Inhibitors in Patients with Rheumatoid Arthritis
Indian Journal of Rheumatology · 06.07.2026
DOI: 10.1177/09733698261454002 ↗Kurz gefasst
Fachartikel in der Zeitschrift Indian Journal of Rheumatology, online erschienen am 06.07.2026. Verfasst von Naoki Nakano und 5 weiteren Autor:innen. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objective
To assess the effectiveness and continuation rate of half-dose Janus kinase (JAK) inhibitors in patients with rheumatoid arthritis (RA).
Methods
We conducted a retrospective cohort study of 212 patients who initiated JAK inhibitors at our hospital (standard-dose group: 142; half-dose group: 70). Among 141 patients who continued the same dose for more than 6 months (standard-dose: 99; half-dose: 42), propensity score matching was performed based on age, disease duration, sex, number of prior biologics/JAK inhibitors, baseline CRP, CDAI, glucocorticoid dose, methotrexate dose, and mHAQ score. Matched groups (37 per group) were compared for CRP, CDAI, and mHAQ at 6 months and for changes from baseline. Reasons for discontinuation were analysed in 71 patients who discontinued treatment within 6 months.
Results
At 6 months, the half-dose group showed significantly higher CRP levels and less improvement in mHAQ scores than the standard-dose group. No significant differences were observed in CDAI or other parameters. Discontinuation due to insufficient effectiveness was significantly more frequent in the half-dose group, whereas discontinuation due to adverse events did not differ between groups.
Conclusions
Compared with standard-dose therapy, half-dose JAK inhibitors are associated with reduced effectiveness and higher discontinuation rates owing to insufficient clinical response.
Zitieren
APA
Nakano, N., Hayashi, S., Tsubosaka, M., Matsumoto, T., Saegusa, J., & Kuroda, R. (2026). Effectiveness and Continuation Rate of Half-dose Janus Kinase Inhibitors in Patients with Rheumatoid Arthritis. Indian Journal of Rheumatology. https://doi.org/10.1177/09733698261454002
Vancouver
Nakano N, Hayashi S, Tsubosaka M, Matsumoto T, Saegusa J, Kuroda R. Effectiveness and Continuation Rate of Half-dose Janus Kinase Inhibitors in Patients with Rheumatoid Arthritis. Indian Journal of Rheumatology. 2026. doi:10.1177/09733698261454002
BibTeX
@article{Nakano2026,
author = {Nakano, Naoki and Hayashi, Shinya and Tsubosaka, Masanori and Matsumoto, Tomoyuki and Saegusa, Jun and Kuroda, Ryosuke},
title = {Effectiveness and Continuation Rate of Half-dose Janus Kinase Inhibitors in Patients with Rheumatoid Arthritis},
journal = {Indian Journal of Rheumatology},
year = {2026},
doi = {10.1177/09733698261454002}
}
EUVIMED